What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?-Reference-Cited by-同舟云学术

What is the impact of antithrombotic therapy and risk factors on the frequency of thrombovascular events in patients with metastatic breast cancer receiving epoetin beta?

Published:2009-11 Issue:17 Volume:45 Page:2984-2991
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Aapro Matti,Barnadas Agustí,Leonard Robert C.,Marangolo Maurizio,Untch Michael,Ukarma Lidia,Burger Hans-Ulrich,Scherhag Armin,Osterwalder Bruno

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference30 articles.

1. Phlegmasia alba dolens;Trousseau,1865

2. Venous thrombosis in cancer patients: insights from the FRONTLINE survey;Kakkar;Oncologist,2003

3. Venous thromboemobolism and cancer: risk and outcomes;Lee;Circulation,2003

4. Cancer-associated thrombosis;Bick;N Engl J Med,2003

5. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case–control study;Heit;Arch Intern Med,2000

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ESAs in perioperative anemia management: Who, what, how and why?;Best Practice & Research Clinical Anaesthesiology;2023-10

2. Effect of erythropoiesis-stimulating agents on breast cancer patients: a meta-analysis;Clinical and Experimental Medicine;2022-10-31

3. Disorders of Blood Cell Production in Clinical Oncology;Abeloff's Clinical Oncology;2014

4. Erythropoietin and the vascular wall: The controversy continues;Nutrition, Metabolism and Cardiovascular Diseases;2013-12

5. Physiology and Pharmacology of Erythropoietin;Transfusion Medicine and Hemotherapy;2013